Bruce Ruggeri
Resolve Therapeutics (United States)(US)
Publications by Year
Research Areas
Cancer-related gene regulation, Ubiquitin and proteasome pathways, Melanoma and MAPK Pathways, Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics
Most-Cited Works
- → Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer(2008)146 cited
- → Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E(2011)58 cited
- → Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment(2017)56 cited
- → CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity(2012)47 cited
- → CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma(2012)27 cited
- → 4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors(2011)13 cited
- → Abstract 2919: Discovery of PRT811, a potent, selective, and orally bioavailable brain penetrant PRMT5 Inhibitor for the treatment of brain tumors(2020)9 cited
- → Abstract 1137: PRMT5 inhibition regulates alternative splicing and DNA damage repair pathways in SF3B1 R625G expressing uveal melanoma cells(2021)8 cited
- → Abstract 2915: Preclinical characterization of PRT543, a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5), with broad antitumor activity in in vitro and in vivo models(2020)7 cited
- → Abstract 1138: PRMT5 inhibition downregulates MYB and NOTCH1 signaling, key molecular drivers of adenoid cystic carcinoma(2021)6 cited